Table 5.
Published studies evaluating clinical response to EGFR TKIs in NSCLC patients with exon 20 insertion
| Study | Type of EGFR Exon 20 mutation | Patients treated with EGFR TKIs | ORR to TKI (%) | PFS to TKI | OS |
|---|---|---|---|---|---|
| Tu et al. [18] | Insertion 20 | 12 | 0 | 3.0 (1.3-4.7) | 12.5 (0-25.5) |
| Lund-Iversen et al. [13] | Insertion 20 | 3 | 0 | - | - |
| Arcila et al. [15] | Insertion 20 | 5 | 40 | 2.5 | > 48 mo |
| Naidoo et al. [12] | Insertion 20 | 11 | 27 | - | - |
| Yasuda et al. [17] | Insertion 20 | 19 | 11 | - | - |
| Kuiper et al. [19] | Insertion 20 | 16 | 0 | 2.9 (2.3-3.6) | 9.7 |
| Current study | Insertion 20 | 4 | 25 | 2.6 (0.7-11.4) | 29.4 (9.3-49.6) |
EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor; NSCLC, non-small cell lung cancer; ORR, objective response rate; PFS, progression free survival; OS, overall survival.